Human Gene Therapy
Editor-in-Chief: Terence R. Flotte, MD
Deputy Editors, Europe: Nathalie Cartier, MD and Thierry VandenDriessche, PhD
Deputy Editors, U.S.: Barry J. Byrne, MD, PhD and Mark A. Kay, MD, PhD
Human Gene Therapy Editor: Guangping Gao, PhD
Methods Editor: Hildegard Büning, PhD
Clinical Development Editor: James M. Wilson, MD, PhD
ISSN: 1043-0342 • Online ISSN: 1557-7422 • Published 22 issues annually
Current Volume: 28
Latest Impact Factor* is 4.062
*2015 Journal Citation Reports® published by Thomson Reuters, 2016
Human Gene Therapy Celebrates 25 Years!
A Video Message from James M. Wilson
In a brand new video message, James M. Wilson, MD, PhD, Editor of Human Gene Therapy Clinical Development, shares exciting news about the Journal's 25th Anniversary and how you can get involved in the celebration!
Winners of the 12 Pioneer Awards for Seminal Work in Gene and Cell Therapy
Interview Series by Editor-in-Chief James M. Wilson
Interview between Editor-in-Chief James M. Wilson, MD, PhD and Pioneer winner Ron Crystal, MD on his “eureka” moment and views on the future of the field. Dr. Crystal's Perspective can be found here.
Ronald G. Crystal, MD, Weill Cornell Medical College, Cornell University
Nominated for: Adenoviral vectors/role in translation of gene therapy to clinic
GEN interviews Dr. James Wilson
Dr. James Wilson is a professor in the department of pathology and laboratory medicine, and the director of the gene therapy program, at the University of Pennsylvania. During this interview with GEN, Dr. Wilson discusses his concept of a disruptive technology and explains why he believes gene therapy falls into this category. In addition to this SKYPE interview, Dr. Wilson further elaborated on his view of gene therapy as a disruptive technology in a column in the January 2012 issue of Human Gene Therapy which can be viewed here.
Human Gene Therapy Podcast Series
Dr. James Wilson
Dr. James Wilson interviews leading members in the field of gene therapy including Andrew Baker & Lynda Coughlan from the University of Glasgow, Luigi Naldini from the San Raffaele Telethon Institute for Gene Therapy, Thierry VandenDriessche from the Free University of Brussels & the University of Leuven in Belgium, and Seppo Yla-Herttuala of ESGCT.
*Audio plays in a popup window. Please make sure your popup blocker is off.
Dr. Terence R. Flotte, Dean of University of Massachusetts Medical School, discusses the role of gene and cell therapy in the era of health care reform. Featured commentary from Dr. Flotte, and co-author Walter H. Ettinger, on the topic is available here.
Thierry VandenDriessche, Professor in Medicine for the Free University of Brussels and the University of Leuven in Belgium, discusses the use of vector AAV to treat patients with hemophilia B.
Andrew Baker discusses his approach of targeting vectors to endothelial cells of vascular grafts, among other newsworthy topics.
Lynda Coughlan, Research Associate at the University of Glasgow and an advocate for early-career researchers to the British Society for Gene Therapy, has organized a workshop to be held at the ESGCT conference on "Careers in Science." She describes what the session will hold.
Luigi Naldini, the Scientific Director for the San Raffaele Telethon Institute for Gene Therapy in Milano, Italy, discusses the progress, benefits, and possible challenges of ex vivo lentiviral gene transfer techniques.
Thierry VandenDriessche, Professor in Medicine for the Free University of Brussels and the University of Leuven in Belgium, discusses the great advancements made in the clinical development of gene therapy in European countries.
Seppo Yla-Herttuala, President of the ESGCT, discusses the expanding field of cell and gene therapy—from important advances to upcoming challenges—as well as updates from his own current research.
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.